ARKG Holdings of SURF
Surface Oncology
Surface Oncology is a biotechnology company that specializes in developing cancer immunotherapies designed to modulate the tumor microenvironment and enhance the body's immune response against cancer. Surface Oncology generates revenue primarily through collaborations and licensing agreements with other pharmaceutical companies, where they receive milestone payments and royalties related to the development and commercialization of their therapies.
Trades of SURF in ARKG
The ten most recent trades of Surface Oncology in the ARKG ETF.View all trades
Date | Direction | Market Value | % of Position | % of ETF |
|---|---|---|---|---|
| Jul 31, 2023 | Sell | $46 | 49.49% | 0.00% |
| Jul 28, 2023 | Sell | $96 | 50.00% | 0.00% |
| Jul 21, 2023 | Sell | $3,760 | 78.65% | 0.00% |
| Jul 18, 2023 | Sell | $90,299 | 92.29% | 0.00% |
| Jul 17, 2023 | Sell | $264,097 | 73.64% | 0.01% |
| Jul 11, 2023 | Sell | $10,852 | 2.81% | 0.00% |
| Jul 07, 2023 | Sell | $184,649 | 20.65% | 0.01% |
| Jun 27, 2023 | Sell | $214,601 | 15.07% | 0.01% |
| Jun 23, 2023 | Sell | $424,550 | 23.41% | 0.02% |
| Jun 21, 2023 | Sell | $1,488,993 | 43.00% | 0.07% |